Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.

TransMedics Stock Plunges 57.5% in Three Months: What's Next?

ANDOVER, Mass. , Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics.

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Is TransMedics Stock a Buy Before 2025?

BioNTech SE

Walgreens

I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond.

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

TransMedics Group (TMDX 3.03%) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August.

Down Over 60%, Is TransMedics Stock a Buy on the Dip?

Shares of Transmedics Group (TMDX 2.13%) sank over 20% this week, according to data from S&P Global Market Intelligence. The organ transplant disrupter announced a CFO transition and reduced the range for its full-year 2024 guidance, indicating slowing revenue growth.

Why Transmedics Group Stock Plummeted 21% This Week

TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance. The company faces near-term challenges, but long-term growth prospects remain strong. The CEO suggested a temporary pause in growth at the Piper Sandler conference this week, with stronger performance expected in 2H 2025, driven by clinical data from heart and lung programs.

TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024

SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- The law firm of  Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-transmedics-group-inc-investigation-tmdx.html   You can also contact attorneys J.C.

TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Shares of leading organ transplant platform TransMedics (TMDX -15.43%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.

Why TransMedics Stock Plummeted Today

Zscaler

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday.

Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr.

TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

TransMedics is facing a softness in demand for transplant services in the United States. Moreover, rising costs raise concern.

Is TMDX Stock a Buy, Sell or Hold at a P/S Multiple of 5.02X?

ANDOVER, Mass. , Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.

TransMedics to Host Investor & Analyst Day on December 10, 2024

In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.

1 Top Growth Stock Down 56% to Buy After Its Recent Pullback

Shopify

2 Hypergrowth Stocks That Are Screaming Buys in November

ANDOVER, Mass. , Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace.

TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference

TMDX's Q3 revenue miss and margin contraction are short-term issues; long-term growth potential remains strong with management's guidance of 4,000 transplants this year and 10,000 in 3-5 years. High expectations led to a stock price drop, but management's clear communication on seasonal trends and market share stability supports the long-term thesis. TMDX is undervalued compared to peers like Intuitive Surgical and PROCEPT BioRobotics, with significant revenue growth potential and a unique market position.

TransMedics: Long-Term Thesis Hasn't Changed At All

This organ transplant specialist is down, but still has plenty of signs of life.

Is TransMedics Group Stock a Buy?

TransMedics' Q3 results were weak, with revenue declining sequentially due to US transplant volume headwinds and scheduled aircraft maintenance. While the growth of TransMedics' current business is likely to continue moderating, there remain large opportunities internationally and in other organs. This is highlighted by the fact that TransMedics reiterated its longer-term transplant volume target, despite current weakness.

TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

Shareholders that Lost Money on TransMedics Group, Inc. (TMDX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TMDX

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

TMDX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by TransMedics Group, Inc.

Sales growth is tapering off for this provider of delivery services for transplant organs.

Down 52%, Is TransMedics Stock a Buy on the Dip?

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

ATTENTION TransMedics Group, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether TransMedics Group, Inc. (“TransMedics Group” or the “Company”) (NASDAQ: TMDX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO LEARN MORE TransMedics Group operates an organ transplant ecosystem under.

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)

The organ transplant specialist posted disappointing results in its third-quarter report.

News for Transmedics Group Inc Stock (TMDX)